The SOLX® system is a whole blood collection system that produces Leukoreduced red blood cells and plasma.

FORT DETRICK, Md. -- In partnership with the U.S. Army Medical Materiel Development Activity, Hemerus Medical LLC received U.S. Food and Drug Administration approval of the New Drug Application for its SOLX® System (LEUKOSEP® HWB-600-XL Leukocyte Reduction Filtration System for Whole Blood with CPD Anticoagulant and SOLX® Additive) April 25.

The SOLX® system is a whole blood collection system that produces Leukoreduced red blood cells and plasma. This system has been approved in the United States by the FDA for six weeks red blood cell storage and was previously approved in Europe for eight weeks red blood cell storage.

"The significant part of the SOLX® System is the additive solution that was co-developed by Walter Reed Army Institute of Research and the University of Cincinnati," said Andrew Atkinson, product manager for the Pharmaceutical Systems Project Management Office at USAMMDA.

"The idea for this product evolved from a 1996 meeting between Col. John R. Hess, M.D., M.P.H. from WRAIR, and the late Dr. Tibor Greenwald from the Hoxworth Blood Center, Cincinnati," said Victor Macdonald, product manager and blood products subject matter expert for PSPMO at USAMMDA. "Col. Hess broached the possibility that changing the formulation of the additive solution used to preserve packed red blood cells might allow refrigerated storage beyond the usual 42 days."

According to Macdonald, the initial driving force behind this effort was the calculation that an additional two weeks of storage time could save the DOD millions of dollars per year in transportation costs and decreased product loss due to product expiration during military deployments. However, it was soon realized that longer storage time only occurred with better quality cells.

"This then was the genesis of a fruitful collaboration between the Army and academia, resulting in a number of peer-reviewed publications that proved the initial concept," said Macdonald. "After years of effort, a partnership was formed with industry for further development of the storage solution and incorporation into a blood collection system with commercial potential."

"It has been over 15 years since a red blood cell storage solution was approved by the FDA," said Atkinson. "The additive solution has been shown to reduce storage lesions, thus improving the quality of the red blood cells and extending the storage period, potentially improving patient outcomes in transfusion."

The need to reduce waste and increase quality is what continues to drive this research in an effort to provide medical advances to save our wounded service members.

According to Atkinson, the future for this product includes implementing a Low Rate Initial Production contract where the Army Blood Program Office can purchase the SOLX® product and obtain the subsequent military blood bank Biologic License Application approvals for the plasma and red blood cells so they can begin using the system.

Partners for this effort include the USAMMDA, WRAIR, University of Cincinnati, and Hemerus Medical LLC, recently acquired by Haemonetics Corporation. Haemonetics will continue to support this effort as the product's Sponsor, and is considered the manufacturer by the FDA.

For product information contact:
Andrew Atkinson
Product Manager
Pharmaceutical Systems Project Management Office
U.S. Army Medical Materiel Development Activity
301-619-5114
Andrew.j.atkinson6.civ@mail.mil

Dr. Victor Macdonald
Product Manager
Pharmaceutical Systems Project Management Office
U.S. Army Medical Materiel Development Activity
301-619-2199
Victor.w.macdonald.civ@mail.mil

Page last updated Mon July 1st, 2013 at 14:48